Skip to main content

Table 4 Response rates after 1 year of treatment with a second tumor necrosis factor inhibitor, stratified by the reason of discontinuation of the first tumor necrosis factor inhibitor

From: Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort

Response criterion

Analysis

Number of patients

All

PLR

SLR

AE

Other

p Valuea

p Valueb

Patients with a clinical diagnosis of axSpA

         

 ASDAS-ESR <2.1

Response/tolerance

184

28.8

11.1

38.9

26.2

38.9

0.01

0.002

 ASDAS-ESR <2.1

Per protocol

124

42.7

21.7

50.8

35.5

63.6

0.04

0.02

 ASDAS-ESR <1.3

Response/tolerance

184

14.7

4.4

21.5

9.5

22.2

0.03

0.01

 ASDAS-ESR <1.3

Per protocol

124

21.8

8.7

28.8

12.9

36.4

0.07

0.08

 ASAS-PR

Response/tolerance

227

11.0

2.0

12.5

13.7

16.7

0.08

0.04

 ASAS-PR

Per protocol

146

17.1

4.2

17.4

18.4

33.3

0.12

0.17

Patients fulfilling the ASAS axSpA classification

 ASDAS-ESR <2.1

Response/tolerance

148

31.1

9.1

40.9

29.0

38.9

0.01

0.001

 ASDAS-ESR <2.1

Per protocol

100

46.0

18.8

55.1

37.5

63.6

0.04

0.02

 ASDAS-ESR <1.3

Response/tolerance

148

16.2

3.0

22.7

12.9

22.2

0.045

0.02

 ASDAS-ESR <1.3

Per protocol

100

24.4

6.2

30.6

16.7

36.4

0.13

0.09

 ASAS-PR

Response/tolerance

179

11.7

0.0

12.5

16.7

18.5

0.03

0.03

 ASAS-PR

Per protocol

106

18.1

0.0

17.5

21.4

35.7

0.05

0.10

  1. axSpA axial spondyloarthritis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score using C-reactive protein, ASDAS-ESR Ankylosing Spondylitis Disease Activity Score using erythrocyte sedimentation rate, AE adverse events, PLR primary lack of response, SLR secondary lack of response
  2. Other refers to reason of discontinuation other than lack of effect or intolerance. Response/tolerance refers to proportion of patients with a valid follow-up achieving the respective response criterion (with patients having discontinued treatment being defined as nonresponders). Per protocol refers to proportion of patients achieving the respective response criterion among those patients still receiving treatment
  3. Except where indicated otherwise, values are percentages
  4. a p Value overall
  5. b p Value PLR vs. SLR